Actions of Vergonil in details
Vergonil Atlantic Laboratories is a loop diuretic. This medication violates the reabsorption of sodium and chlorine in the large segment of the ascending loop of Henle. Due to increasing separation of sodium ions occurs secondary (indirect osmotically bound water) increased excretion of water and increased secretion of potassium ions in the distal renal tubule. Simultaneously increased excretion of calcium and magnesium ions.
Vergonil has secondary effects caused by the release of neurotransmitters and intrarenal redistribution of intrarenal blood flow. On the background of a course of treatment does not occur the weakening effect.
When heart failure Vergonil Atlantic Laboratories quickly leads to a reduction of preload on the heart through the expansion of large veins. This drug exerts the hypotensive effect due to increased excretion of sodium chloride and reduction reactions of vascular smooth muscle to vasoconstrictor effects and by decreasing the BCC. Effect of Vergonil after IV injection occurs in 5-10 minutes; after oral administration within 30-60 minutes, a maximum of the action is after 1-2 hours, the duration of effect is 2-3 hours (if reduced kidney function - up to 8 hours).
Vergonil Atlantic Laboratories reduces the incidence of atrial natriuretic factor in the plasma, causing vasoconstriction.
Diuretic effect develops in 3-4 minutes after IV injection and lasts 1-2 h; after oral taking - 20-30 minutes, lasts up to 4 hours.
How should I take Vergonil?
Take Vergonil exactly as prescribed by your doctor. Follow all directions on your prescription label. Your doctor may occasionally change your dose to make sure you get the best results. Do not use this medicine in larger or smaller amounts or for longer than recommended.
Do not take more than your recommended dose. High doses of Vergonil may cause irreversible hearing loss.
Measure liquid medicine with the dosing syringe provided, or with a special dose-measuring spoon or medicine cup. If you do not have a dose-measuring device, ask your pharmacist for one.
Vergonil will make you urinate more often and you may get dehydrated easily. Follow your doctor's instructions about using potassium supplements or getting enough salt and potassium in your diet.
While using Vergonil, you may need frequent blood tests.
Keep using this medicine as directed, even if you feel well. High blood pressure often has no symptoms. You may need to use blood pressure medicine for the rest of your life.
If you need surgery, tell the surgeon ahead of time that you are using Vergonil.
Store at room temperature away from moisture, heat, and light. Throw away any Vergonil oral solution (liquid) 90 days after opening the bottle, even if it still contains unused medicine.
Vergonil administration
Take exactly as prescribed by your doctor. Do not take more of this medication than is recommended. High doses of Vergonil may cause irreversible hearing loss. Follow the directions on your prescription label. Your doctor may occasionally change your dose to make sure you get the best results.
Measure liquid medicine with a special dose-measuring spoon or medicine cup, not with a regular table spoon. If you do not have a dose-measuring device, ask your pharmacist for one.
Vergonil will make you urinate more often and you may get dehydrated easily. Follow your doctor's instructions about using potassium supplements or getting enough salt and potassium in your diet.
While using Vergonil, you may need blood tests at your doctor's office. Visit your doctor regularly.
If you are being treated for high blood pressure, keep using this medication even if you feel fine. High blood pressure often has no symptoms.
Store at room temperature away from moisture, heat, and light. Vergonil liquid medicine should be used within 60 to 90 days after opening the bottle. Ask your pharmacist how many days your medicine is good for. Throw away any unused liquid after that time has passed.
Vergonil pharmacology
Investigations into the mode of action of Vergonil have utilized micropuncture studies in rats, stop flow experiments in dogs and various clearance studies in both humans and experimental animals. It has been demonstrated that Vergonil inhibits primarily the absorption of sodium and chloride not only in the proximal and distal tubules but also in the loop of Henle. The high degree of efficacy is largely due to the unique site of action. The action on the distal tubule is independent of any inhibitory effect on carbonic anhydrase and aldosterone.
Recent evidence suggests that Vergonil glucuronide is the only or at least the major biotransformation product of Vergonil in man. Vergonil is extensively bound to plasma proteins, mainly to albumin. Plasma concentrations ranging from 1 to 400 mcg/mL are 91 to 99% bound in healthy individuals. The unbound fraction averages 2.3 to 4.1% at therapeutic concentrations.
The onset of diuresis following oral administration is within 1 hour. The peak effect occurs within the first or second hour. The duration of diuretic effect is 6 to 8 hours.
In fasted normal men, the mean bioavailability of Vergonil from Vergonil Tablets and Vergonil oral solution is 64% and 60%, respectively, of that from an intravenous injection of the drug. Although Vergonil is more rapidly absorbed from the oral solution (50 minutes) than from the tablet (87 minutes), peak plasma levels and area under the plasma concentration-time curves do not differ significantly. Peak plasma concentrations increase with increasing dose but times-to-peak do not differ among doses. The terminal half-life of Vergonil is approximately 2 hours.
Significantly more Vergonil is excreted in urine following the IV injection than after the tablet or oral solution. There are no significant differences between the two oral formulations in the amount of unchanged drug excreted in urine.
Geriatric Population
Vergonil binding to albumin may be reduced in elderly patients. Vergonil is predominantly excreted unchanged in the urine. The renal clearance of Vergonil after intravenous administration in older healthy male subjects (60 to 70 years of age) is statistically significantly smaller than in younger healthy male subjects (20 to 35 years of age).The initial diuretic effect of Vergonil in older subjects is decreased relative to younger subjects.
References
- DailyMed. "FUROSEMIDE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
- NCIt. "Furosemide: NCI Thesaurus (NCIt) provides reference terminology for many systems. It covers vocabulary for clinical care, translational and basic research, and public information and administrative activities.". https://ncit.nci.nih.gov/ncitbrowser... (accessed September 17, 2018).
- EPA DSStox. "Furosemide: DSSTox provides a high quality public chemistry resource for supporting improved predictive toxicology.". https://comptox.epa.gov/dashboard/ds... (accessed September 17, 2018).
Reviews
The results of a survey conducted on ndrugs.com for Vergonil are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Vergonil. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
Consumer reported administration
No survey data has been collected yetConsumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
